- Title
- Systemic treatment of HER2-positive metastatic breast cancer: a systematic review
- Creator
- Wilcken, Nicholas; Zdenkowski, Nicholas; Chua, Sue; Chirgwin, Jacquie; Beith, Jane; Bell, Richard; White, Michelle; Snyder, Ray; Pittman, Ken; Mainwaring, Paul; Green, Michael; Francis, Prudence; De Boer, Richard; Colosimo, Maree
- Relation
- Asia Pacific Journal of Clinical Oncology Vol. 10, Issue S4, p. 1-14
- Publisher Link
- http://dx.doi.org/10.1111/ajco.12206
- Publisher
- Wiley-Blackwell Publishing
- Resource Type
- journal article
- Date
- 2014
- Description
- Aim: We aimed to systematically review and summarize data from the available clinical trials that examined the treatment of HER2-positive metastatic breast cancer. Methods: We reviewed phase 2 and 3 studies in which an anti-HER2 agent was used in one or both arms of the study. While formal meta-analysis was not possible for such a heterogeneous group of trials, resulting forest plots outline some generalizable findings. Results: There is strong evidence that the addition of an anti-HER2 agent to standard chemo- or endocrine therapy improves clinically relevant measurable outcomes. There is also consistent evidence that initial treatment with trastuzumab alone (and subsequent use of a cytotoxic) is inferior to the initial combination of trastuzumab plus chemotherapy, and that either T-DM1 or dual anti-HER2 agents are superior to single anti-HER2 agent regimens. There is no strong evidence that the use of more than one cytotoxic agent together with an anti-HER2 agent confers any benefit over a single cytotoxic, anti-HER2 combination. Conclusion: This review provides a strong evidence base for current clinical practice with a discussion of treatment in the Australian setting.
- Subject
- anti-HER2 agent; breast cancer; metastatic; review; systematic
- Identifier
- http://hdl.handle.net/1959.13/1302818
- Identifier
- uon:20551
- Identifier
- ISSN:1743-7555
- Language
- eng
- Reviewed
- Hits: 8931
- Visitors: 8835
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|